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Abstract
BACKGROUND—Objective of this analysis was to identify predictors of death, failure, and 
default among MDR-TB patients treated with second-line drugs in DOTS-plus projects in Estonia, 
Latvia, Philippines, Russia, and Peru, 2000–2004.
METHODS—Risk ratios (RR) with 95% confidence intervals (CI) were calculated using 
multivariable regression.
RESULTS—Of 1,768 patients, treatment outcomes were: cure/completed – 1,156 (65%), died – 
200 (11%), default - 241 (14%), failure - 118 (7%). Independent predictors of death included: 
age>45 years (RR=1.90 (95%CI 1.29–2.80), HIV infection (RR=4.22 (2.65–6.72)), 
extrapulmonary disease (RR=1.54 (1.04–2.26)), BMI<18.5 (RR=2.71 (1.91–3.85)), previous use 
of fluoroquinolones (RR=1.91 (1.31–2.78)), resistance to any thioamide (RR=1.59 (1.14–2.22)), 
baseline positive smear (RR=2.22 ()1.60–3.10), no culture conversion by 3rd month of treatment 
(RR=1.69 (1.19–2.41)); failure: cavitary disease (RR=1.73 (1.07–2.80)), resistance to any 
fluoroquinolone (RR=2.73 (1.71–4.37)) and any thioamide (RR=1.62 (1.12–2.34)), and no culture 
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conversion by 3rd month (RR=5.84 (3.02–11.27)); default: unemployment (RR=1.50 (1.12–2.01)), 
homelessness (RR=1.52 (1.00–2.31)), imprisonment (RR=1.86 (1.42–2.45)), alcohol abuse 
(RR=1.60 (1.18–2.16)), and baseline positive smear (RR=1.35 (1.07–1.71)).
CONCLUSION—Patients with biomedical risk factors for treatment failure or death should 
receive heightened medical attention. To prevent treatment default, management of patients who 
are unemployed, homeless, alcoholic, or have a prison history requires extra measures to insure 
treatment completion.
Keywords
multidrug-resistant tuberculosis; treatment outcomes; risk factors
Introduction
Modern chemotherapy of drug-susceptible tuberculosis (TB) has >95% efficacy in 
randomized, controlled clinical trials, and the new World Health Organization (WHO) target 
for treatment success rates for TB Control programs is 90% by 2015.1 Treatment of 
multidrug-resistant (MDR) TB (i.e., TB caused by strains of Mycobacterium tuberculosis 
resistant to at least isoniazid and rifampicin) has far worse outcomes as summarized in two 
recent systematic reviews and meta-analyses.2, 3 Treatment of MDR-TB is more expensive, 
longer, and more toxic compared with standardized short-course chemotherapy for drug-
susceptible TB.4
In 2000, the Green Light Committee (GLC) was formed to increase access to quality-
assured second-line drugs (SLDs) at reduced prices while at the same time preventing the 
emergence of further drug resistance. From February 1999 to August 2001 the first five 
DOTS-plus projects approved by the GLC started treating patients, including Estonia; 
Latvia; Makati Medical Center, Manila, Philippines; the Harvard/Partners in Health Project 
in northern Lima, Peru; and Tomsk Oblast, Russia.5, 6 In an effort to improve MDR-TB 
treatment outcomes we analyzed data from these projects focusing on early predictors of 
poor treatment outcomes that should trigger timely clinical re-assessment and further action.
Methods
Study Design and Patient Population
This retrospective cohort included adult patients with MDR-TB starting treatment between 
01/01/2000–12/31/2003 in five GLC-approved DOTS-Plus programs.6 The majority of 
patients in Russia, Latvia, and Estonia were hospitalized, while most patients in Peru and the 
Philippines received treatment as outpatients. Patients received individualized treatment 
regimens including 5–7 drugs (typically including a fluoroquinolone and injectable second-
line drug) to ensure at least four drugs were effective, in accordance with the GLC-approved 
protocols.7 The study was approved by the U.S. Centers for Disease Control and Prevention 
Institutional Review Board (IRB) and IRBs at all participating sites.
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Definitions
Treatment outcomes were programmatically assigned according to each site’s criteria. 
Consensus definitions were developed from 2000–2002 by an international panel of experts 
including representatives of these five projects and were used in GLC-approved pilot 
projects before their formal publication in 2005.8 Positive smear, positive culture, and 
culture conversion were defined according to WHO guidelines.4 Baseline drug resistance 
was determined by drug susceptibility tests (DST) in the local laboratory from sputum 
collected between 60 days prior to 30 days after MDR-TB treatment initiation. Extensively 
drug-resistant (XDR) TB and SLDs groups were defined according WHO guidelines.4
Data Collection and Statistical Analysis
The database was compiled from existing electronic medical records from five countries. 
Common variables were identified, common data definitions were operationalized, and 
disparate data formats were harmonized as previously described6. Statistical analyses were 
performed using SAS software, version 9.1 (SAS Institute Inc., Cary, NC). Risk ratios (RR) 
with 95% confidence intervals (CI) for each of the poor outcomes (death, failure, and 
default) were calculated using log-binomial regression. Factors significant at a value of P≤.
05 in the univariate analysis as well as factors with plausible epidemiological or biological 
association with each outcome of interest were included in a multivariable log-binomial 
regression model. Confounding and interaction were assessed. Backward selection was used 
to choose prognostic variables for final models. A P value of ≤0.05 was considered 
statistically significant.
Results
A total of 1,768 patients were included in analysis: 663 (37.5%) from Peru, 444 (25.1%) 
from Latvia, 280 (15.8%) from Estonia, 221 (12.5%) from Russia and 160 (9.1%) from the 
Philippines. The majority of patients were males (70%), median age was 36 years, and 1.6% 
were HIV-infected. Socio-demographic and clinical characteristics of this cohort were 
previously reported by Gammino et al.6 Pre-treatment isolates were resistant to a median 
and mean of 5 (interquartile range [IQR] 4–6; range 2–11) first- and second-line anti-TB 
drugs at the start of treatment. A total of 57 (4.7%) of 1,221 patients with available DST 
result for at least one injectable SLD and fluoroquinolone had extensively drug resistant 
tuberculosis at the start of treatment (ranged between sites from 2.9% to 7.9%).
Overall 92.9% (756 of 832 patients with available information) had at least one adverse 
event reported, with a median of 2 (mean 2.4±1.5; range 0–8) adverse event types per 
patient (Table 1). The most commonly recorded adverse events of treatment with second-
line drugs included nausea (n=540, 65.6%), diarrhea (n=249, 30.3%), and ototoxicity/
hearing disturbances (n=130, 15.8%).
Of 1,768 patients, treatment outcomes were: cure/completed – 1,156 (65.4%), died – 200 
(11.3%), failure - 118 (6.7%), default - 241 (13.6%), transferred/unknown - 53 (3.0%). The 
exact outcome dates were not available, but using the length of microbiological monitoring 
as a proxy for the length of treatment, patients in whom treatment was successful were on 
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treatment for median of 21 months (IQR 17–25), patients who died - 8.5 months (IQR 2–
16), patients who defaulted treatment – 8 months (IQR 3–15), and those in whom treatment 
failed – 13 months (IQR 7–23). Of 57 patients with XDR TB, treatment outcomes were: 31 
(54.4%) patients had cure/completed treatment, 10 (17.5%) died, 13 (22.8%) failed, and 3 
(5.3%) defaulted.
Results of univariate and multivariable analysis of predictors of poor treatment outcomes are 
shown in Tables 2–4. In multivariable analysis independent risk factors for death included 
age>45 years (RR=1.90 (95%CI 1.29–2.80), HIV infection (RR=4.22 (2.65–6.72)), 
extrapulmonary with pulmonary 6 disease (RR=1.54 (1.04–2.26)), BMI<18.5 (RR=2.71 
(1.91–3.85)), previous use of fluoroquinolones (RR=1.91 (1.31–2.78)), resistance to any 
thioamide (RR=1.59 (1.14–2.22)), baseline positive smear (RR=2.22 (1.60–3.10)), and no 
culture conversion by 3rd month of treatment (RR=1.69 (1.19–2.41)). Patients with prior 
contact with any TB patient had decreased risk of death (RR=0.10 (0.01–0.68)). Treatment 
failure was associated in multivariable analysis with cavitary disease (RR=1.73 (1.07–
2.80)), resistance to any fluoroquinolone (RR=2.73 (1.71–4.37)) and any thioamide 
(RR=1.62 (1.12–2.34)), and no culture conversion by 3rd month (RR=5.84 (3.02–11.27)). 
Independent predictors of default in multivariable analysis included unemployment 
(RR=1.50 (1.12–2.01)), homelessness (RR=1.52 (1.00–2.31)), imprisonment (RR=1.86 
(1.42–2.45)), alcohol abuse (RR=1.60 (1.18–2.16)), and baseline positive smear (RR=1.35 
(1.07–1.71)).
Discussion
In summary, despite the use of DOTS-plus to treat this large retrospective cohort of 1,768 
patients with drug-resistant tuberculosis, treatment succeeded only in 65% of patients, while 
32% had poor treatment outcomes, including death (11%), failure (7%), and default (14%). 
Treatment outcomes were strikingly similar to the results of two recent meta-analyses and 
recent surveillance data from 71 countries.9 Johnston et al2 reported from 36 studies that 
62% of patients achieved successful outcomes, while 11% died, 8% failed, and 13% 
defaulted. Orenstein et al3 reported a mean proportion of patients with treatment success in 
29 studies of individualized treatment regimens for MDR-TB was 64%, while 11% died, 6% 
failed, and 12% defaulted treatment. Surveillance data from 71 countries or territories on 
treatment outcomes for MDR-TB cases showed similar overall treatment success rate (60% 
after adjustment for clustering by countries) and deaths (8%-13% in new and retreatment 
cases).9
When patients are heading for a poor outcome, prompt action by the physician/program is 
required. This may include repeating or broadening DST, changing treatment, social/
behavioral support, surgery, and further evaluation. Death and treatment failure were 
associated mainly with biomedical factors, while default from treatment was associated 
mostly with social factors.
Independent predictors of death and failure, including HIV infection, low body mass index, 
extensive disease, previous treatment with specific drugs, baseline positive smear, additional 
resistance to specific drugs, and persistently positive cultures at the 3rd month of treatment 
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should trigger additional steps and may be amenable to specific interventions. Older age, 
HIV infection, and extensive TB disease are well-known risk factors for mortality of 
patients with tuberculosis.10 Association of prior contact with any TB patient with reduced 
mortality may be related to earlier diagnosis of MDR TB through contact investigation. 
Malnutrition, positive baseline smear, and delayed culture conversion were previously 
demonstrated as risk factors for poor outcomes of MDR-TB treatment.2, 11 Our findings 
suggest that fluoroquinolones play an important part in TB treatment, which concurs with 
previous studies demonstrating that fluoroquinolone resistance was associated with poor 
MDR-TB treatment outcomes.2, 12, 13 Regimens for treatment of TB that include 
fluoroquinolones need to be strong enough not to amplify resistance to fluoroquinolones. 
Also patients who receive fluoroquinolones for other reasons (e.g. pneumonia) should be 
screened for TB first. The impact of thioamide resistance on poor outcomes should be 
further studied.
Socioeconomic factors that increase the risk of default such as unemployment, 
homelessness, imprisonment, and alcoholism should trigger different types of measures to 
improve treatment adherence, such as disability stipends, different types of incentives and/or 
enablers, consultation with a social worker, home visiting, reimbursement of transportation 
to/from the place of treatment, psychological counseling, legal consulting, etc.14 
Collaboration between TB services and substance abuse services may improve TB treatment 
adherence, but this needs further research.
Concordantly with previous reports,15–17 we found that adverse events during MDR TB 
treatment were very common – 93% of patients had at least one adverse event reported. 
Gastrointestinal disturbances (nausea and diarrhea) were most often reported side effects. It 
is important to emphasize that adverse events may have a severe impact on adherence to 
treatment, so it is crucial to clinically monitor patients for adverse events and timely manage 
side effects if they occur.4, 7
This study has several limitations. The data were retrospective and not originally collected 
for the purpose of this study; thus there was site-to-site variation in data definitions and 
recording format. We operationalized the variables for this analysis so they would be 
consistent across sites. However, not all sites collected data on the same variables; 
consequently data were missing for individual variables (for up to 30% of observations for 
certain variables) for some sites; however, we included a category for “missing” results as a 
dummy variable in the multivariable regression analysis for variables missing more than 7% 
of data. Data were not available regarding details of treatment, but all sites followed GLC 
approved treatment protocols consisting of at least four effective drugs, generally treating 
with aggressive regimens of five to seven drugs. Treatment outcomes at each of the DOTS-
plus projects were defined by national norms, but these were generally consistent with 
international consensus recommendations developed 2000–2002.8 Generalizability of the 
study findings may be limited to sites with comparable patient populations, i.e. with low 
HIV rates, similar drug-resistance epidemiology, and on individualized MDR-TB treatment.
The overall findings of our study corroborate with findings of recent individual patient data 
(IPD) meta-analysis of 9,153 patients18 which was used to inform the revision of the WHO 
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Guidelines for the Programmatic Management of Drug-resistant Tuberculosis (PMDT)19. 
The median duration of treatment of 21 months among those with success outcome in our 
study was similar to total treatment duration of 18.6–21.5 months associated with increased 
odds of success in IDP meta-analysis. Similarly to Menzies at al18, we found an independent 
association of poor outcomes with fluoroquinolone resistance or use of fluoroquinolone in 
the past for treatment of TB and thioamide resistance, and no independent association of 
resistance to injectable agents with poor treatment outcomes. Thus, the findings of our study 
support current WHO recommendations on including a later generation quinolone and 
thioamide in treatment regimen and total duration of treatment of at least 21 months.19 
Given gross lack of prospective evaluation of MDR regimens (with and without new drugs), 
exemplified by the finding that fluoroquinolones resistance was the strongest risk factor for 
failure, better understanding on how to best combine old drugs with novel drugs in the 
pipeline is also needed. Randomized clinical trials are urgently needed to determine the 
optimal treatment regimens for patients with MDR-TB.
In conclusion, patients with identified biomedical risk factors for death or treatment failure 
should receive targeted medical attention from the beginning of MDR-TB treatment 
including aggressive treatment with maximum number of effective drugs, adjuvant 
interventions, including nutritional supplementation and consideration of surgery. To 
prevent treatment default, management of patients who are unemployed, homeless, 
alcoholic, or have a history of imprisonment requires extra measures to insure treatment 
completion. Operations research should be carried out to identify effective interventions for 
both adherence and treatment outcome improvement in specific settings.
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Table 1
Adverse events on treatment with second-line drugs (N=823)
Adverse event Number (percent*)
Nausea 540 (65.6)
Diarrhea 249 (30.3)
Ototoxicity (hearing disturbances) 130 (15.8)
Headache 95/602** (11.5)
Hypokalemia 99/221** (14.9)
Peripheral neuropathy 76 (9.2)
Hypothyroidism 40 (4.9)
Seizure 39 (4.7)
Psychosis 35/379** (4.3)
Hepatitis 19 (2.3)
Renal insufficiency (elevated creatinine) 15/602** (1.8)
*
Percentage from total 823 unless states otherwise.
**
Denominator is number of patients with available data on particular adverse event.
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